Edition:
India

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

81.21USD
20 Sep 2019
Change (% chg)

-- (--)
Prev Close
$81.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
465,989
52-wk High
$89.30
52-wk Low
$57.01

Latest Key Developments (Source: Significant Developments)

Incyte And Zai Lab Announce Collaboration And License Agreement For Incmga0012 In Greater China
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Incyte Corp ::INCYTE AND ZAI LAB ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR INCMGA0012 IN GREATER CHINA.ZAI LAB LTD - COLLABORATION AND LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF INCMGA0012 IN GREATER CHINA.ZAI LAB LTD - ZAI LAB WILL PAY INCYTE US$17.5 MILLION UP FRONT.ZAI LAB LTD - INCYTE IS ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL US$60 MILLION IN POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES.ZAI LAB LTD - TO GET RIGHTS TO DEVELOP, COMMERCIALIZE INCMGA0012 IN HEMATOLOGY AND ONCOLOGY IN MAINLAND CHINA, HONG KONG, MACAU AND TAIWAN.ZAI LAB LTD - INCYTE WILL RETAIN OPTION TO ASSIST IN PROMOTION OF INCMGA0012 IN ZAI LAB'S LICENSED TERRITORIES.  Full Article

FDA Approves Jakafi For The Treatment Of Patients With Acute Graft-Versus-Host Disease
Friday, 24 May 2019 

May 24 (Reuters) - Incyte Corp ::FDA APPROVES JAKAFI® (RUXOLITINIB) FOR THE TREATMENT OF PATIENTS WITH ACUTE GRAFT-VERSUS-HOST DISEASE.INCYTE CORP - JAKAFI WILL BE MADE AVAILABLE TO APPROPRIATE PATIENTS WITH STEROID-REFRACTORY ACUTE GVHD IMMEDIATELY..INCYTE CORP - FDA APPROVED JAKAFI (RUXOLITINIB) FOR TREATMENT OF STEROID-REFRACTORY ACUTE GVHD IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER.  Full Article

Incyte Corp QTRLY Adjusted Diluted Earnings Per Share $0.62
Tuesday, 30 Apr 2019 

Incyte Corp ::INCYTE REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES UPDATES ON KEY CLINICAL PROGRAMS.Q1 REVENUE $498 MILLION VERSUS REFINITIV IBES ESTIMATE OF $486.2 MILLION.QTRLY BASIC GAAP EARNINGS PER SHARE $0.48.QTRLY DILUTED GAAP EARNINGS PER SHARE $0.47.QTRLY ADJUSTED DILUTED EARNINGS PER SHARE $0.62.QTRLY ADJUSTED BASIC EARNINGS PER SHARE $0.63.PRIMARY ENDPOINT MET IN PHASE 2 TRIAL OF RUXOLITINIB CREAM FOR TREATMENT OF VITILIGO.DECISION TAKEN TO NO LONGER PARTICIPATE IN CO-FUNDING OF DEVELOPMENT OF BARICITINIB.SEES 2019 GAAP RESEARCH AND DEVELOPMENT EXPENSES OF $1,185 MILLION - $1,255 MILLION.Q1 EARNINGS PER SHARE VIEW $0.40, REVENUE VIEW $486.2 MILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $1.94, REVENUE VIEW $2.05 BILLION -- REFINITIV IBES DATA.  Full Article

Incyte Announces U.S. FDA Has Extended The Review Period For Ruxolitinib (Jakafi) In Acute Graft-Versus-Host Disease
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Incyte Corp ::INCYTE ANNOUNCES U.S. FDA HAS EXTENDED THE REVIEW PERIOD FOR RUXOLITINIB (JAKAFI®) IN ACUTE GRAFT-VERSUS-HOST DISEASE.INCYTE CORP - FDA EXTENDED ACTION DATE TO ALLOW TIME TO REVIEW ADDITIONAL DATA SUBMITTED BY INCYTE IN RESPONSE TO FDA'S INFORMATION REQUESTS.INCYTE CORP - AN EXTENSION OF PDUFA GOAL DATE BY THREE MONTHS.INCYTE CORP - NEW PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE IS MAY 24, 2019.  Full Article

Incyte Appoints Christiana Stamoulis As CFO
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Incyte Corp ::INCYTE APPOINTS CHRISTIANA STAMOULIS AS CHIEF FINANCIAL OFFICER.INCYTE CORP - STAMOULIS WILL SUCCEED DAVID GRYSKA WHO, AS PLANNED, RETIRED FROM INCYTE AT END OF 2018.INCYTE CORP - APPOINTMENT OF CHRISTIANA STAMOULIS AS CHIEF FINANCIAL OFFICER EFFECTIVE FEBRUARY 11.  Full Article

Innovent, Incyte Announce Strategic Collaboration And Licensing Agreement
Monday, 17 Dec 2018 

Dec 16 (Reuters) - Incyte Corp ::INNOVENT AND INCYTE ANNOUNCE STRATEGIC COLLABORATION AND LICENSING AGREEMENT FOR THREE CLINICAL-STAGE PRODUCT CANDIDATES IN CHINA.INNOVENT TO PAY CO $40 MILLION IN CASH UP FRONT.CO SHALL BE ELIGIBLE TO RECEIVE ADDITIONAL $20 MILLION IN CONSIDERATION IN CONNECTION WITH FIRST IND APPLICATION BY INNOVENT IN CHINA.FIRST INVESTIGATIONAL NEW DRUG (IND) APPLICATION BY INNOVENT IN CHINA IS EXPECTED TO BE ACHIEVED IN 2019.INNOVENT TO RECEIVE RIGHTS TO DEVELOP, COMMERCIALIZE THREE ASSETS IN HEMATOLOGY AND ONCOLOGY IN MAINLAND CHINA, HONG KONG, MACAU, TAIWAN.TRANSACTION IS EFFECTIVE IMMEDIATELY UPON EXECUTION OF STRATEGIC COLLABORATION AGREEMENT.CO AND INNOVENT BIOLOGICS ENTERED INTO THE STRATEGIC COLLABORATION AGREEMENT THROUGH THEIR RESPECTIVE SUBSIDIARIES.  Full Article

Agenus Receives Milestone Payment From Incyte
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Agenus Inc ::AGENUS RECEIVES MILESTONE PAYMENT FROM INCYTE.AGENUS INC - PAYMENT OF $5M RECEIVED FOR INITIATION OF PHASE 1 TRIAL OF LAG-3 ANTIBODY.AGENUS - ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $505 MILLION IN POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONES FROM INCYTE.  Full Article

Incyte Q2 Non-GAAP Earnings Per Share $0.27
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Incyte Corp ::INCYTE REPORTS 2018 SECOND QUARTER FINANCIAL RESULTS AND UPDATES ON KEY CLINICAL PROGRAMS.Q2 NON-GAAP EARNINGS PER SHARE $0.27.TOTAL PRODUCT-RELATED REVENUES OF $421 MILLION IN Q2 2018, REPRESENTING 29 PERCENT GROWTH OVER SAME PERIOD LAST YEAR.Q2 EARNINGS PER SHARE VIEW $0.34 -- THOMSON REUTERS I/B/E/S.SEES 2018 NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE $1,008 - $1,103 MILLION.  Full Article

Incyte, Merck Provide Update On Phase 3 Study
Friday, 6 Apr 2018 

April 6 (Reuters) - Incyte Corp ::INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.STUDY'S SECOND PRIMARY ENDPOINT OF OVERALL SURVIVAL ALSO IS NOT EXPECTED TO REACH STATISTICAL SIGNIFICANCE.BASED ON RESULTS, AND AT RECOMMENDATION OF EDMC, PHASE 3 STUDY WILL BE STOPPED.252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA.252 STUDY EVALUATING EPACADOSTAT WITH KEYTRUDA DETERMINED STUDY DID NOT MEET PRIMARY ENDPOINT.  Full Article

Incyte Corp Q4 Loss Per Share $0.71
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Incyte Corp ::INCYTE REPORTS 2017 FOURTH-QUARTER AND YEAR-END FINANCIAL RESULTS, PROVIDES 2018 FINANCIAL GUIDANCE AND UPDATES ON KEY CLINICAL PROGRAMS.Q4 REVENUE ROSE 36 PERCENT TO $444 MILLION.Q4 LOSS PER SHARE $0.71.Q4 EARNINGS PER SHARE VIEW $-0.45, REVENUE VIEW $426.0 MILLION -- THOMSON REUTERS I/B/E/S.INCYTE - IN 2018 CO TO BEGIN REPORTING CERTAIN NON-GAAP FINANCIAL MEASURES, TO BE CONSIDERED IN CONJUNCTION WITH CO'S GAAP REPORTING.QTRLY NON-GAAP NET INCOME WAS $4 MILLION.  Full Article

Incyte's Jakafi gets FDA approval to treat Graft vs Host Disease

The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.